文献速递胸部肿瘤

PD-L1检测对非小细胞肺癌二线免疫检查点抑制剂治疗的成本效果及经济影响

The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC.
PubMed 文献 · Ann Oncol · 2017-01-01

该决策分析模型基于4项随机临床试验和美国药品采购成本,评估PD-L1检测筛选后使用纳武利尤单抗、帕博利珠单抗或阿替利珠单抗二线治疗非小细胞肺癌的成本效果与经济影响,发现PD-L1表达筛选可提高成本效果但减少潜在生命年获益人数。

要点

  • 纳武利尤单抗增量QALY在鳞癌为0.417、非鳞癌为0.287,ICER分别为155605美元和187685美元。
  • 阿替利珠单抗基础病例QALY增益0.354,ICER为215802美元。
  • 帕博利珠单抗仅在PD-L1表达患者中研究,QALY增益0.346,ICER为98421美元。

核心结论

  • 使用PD-L1表达作为生物标志物可提高免疫治疗的成本效果,但也减少潜在生命年获益人数。

研究设计与样本

  • 开发决策分析模型,评估PD-L1评估及二线免疫治疗对比多西他赛的成本效果,模型使用随机临床试验结局数据及美国药品采购成本,并利用流行病学数据估算治疗的经济影响。

主要发现

  • 纳入4项随机临床试验(2项纳武利尤单抗、1项帕博利珠单抗、1项阿替利珠单抗)。
  • 纳武利尤单抗增量QALY在鳞状肿瘤为0.417、非鳞状肿瘤为0.287,ICER分别为155605美元和187685美元。
  • 阿替利珠单抗基础病例QALY增益为0.354,ICER为215802美元。
  • 与治疗所有患者相比,通过PD-L1表达筛选患者使增量QALY提高最多183%,ICER降低最多65%。
  • 帕博利珠单抗仅在肿瘤表达PD-L1的患者中研究,QALY增益为0.346,ICER为98421美元。

关键数值与推荐

  • 纳武利尤单抗鳞状肿瘤增量QALY 0.417,ICER 155605美元;非鳞状肿瘤增量QALY 0.287,ICER 187685美元。
  • 阿替利珠单抗基础病例QALY增益0.354,ICER 215802美元。
  • 帕博利珠单抗QALY增益0.346,ICER 98421美元。
  • PD-L1表达筛选使增量QALY提高最多183%,ICER降低最多65%。

临床怎么用

  • 患者筛选也降低了免疫治疗的预算影响。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Immune checkpoint inhibitors improve outcomes compared with chemotherapy in lung cancer. Tumor PD-L1 receptor expression is being studied as a predictive biomarker. The objective of this study was to assess the cost-effectiveness and economic impact of second-line treatment with nivolumab, pembrolizumab, and atezolizumab with and without the use of PD-L1 testing for patient selection. DESIGN: We developed a decision-analytic model to determine the cost-effectiveness of PD-L1 assessment and second-line immunotherapy versus docetaxel. The model used outcomes data from randomized clinical trials (RCTs) and drug acquisition costs from the United States. Thereafter, we used epidemiologic data to estimate the economic impact of the treatment. RESULTS: We included four RCTs (2 with nivolumab, 1 with pembrolizumab, and 1 with atezolizumab). The incremental quality-adjusted life year (QALY) for nivolumab was 0.417 among squamous tumors and 0.287 among non-squamous tumors and the incremental cost-effectiveness ratio (ICER) were $155 605 and $187 685, respectively. The QALY gain in the base case for atezolizumab was 0.354 and the ICER was $215 802. Compared with treating all patients, the selection of patients by PD-L1 expression improved incremental QALY by up to 183% and decreased the ICER by up to 65%. Pembrolizumab was studied only in patients whose tumors expressed PD-L1. The QALY gain was 0.346 and the ICER was $98 421. Patient selection also reduced the budget impact of immunotherapy. CONCLUSION: The use of PD-L1 expression as a biomarker increases cost-effectiveness of immunotherapy but also diminishes the number of potential life-years saved.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Aguiar PN, Perry LA, Penny-Dimri J, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017. PMID: 28633409. doi:10.1093/annonc/mdx305

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。